UC BON.CAP.CERT. 09/24 LLY/ DE000HD5P1C5 /
8/12/2024 1:46:51 PM | Chg.-1.360 | Bid2:27:47 PM | Ask8/12/2024 | Underlying | Strike price | Expiration date | Option type |
---|---|---|---|---|---|---|---|
847.950EUR | -0.16% | 847.950 Bid Size: 80 |
- Ask Size: 80 |
ELI LILLY | - - | 9/27/2024 | Call |
GlobeNewswire
7/1
Ovid Therapeutics and Graviton Bioscience Announce Topline Data from a Phase 1 Clinical Trial Studyi...
GlobeNewswire
6/28
Atossa Therapeutics Announces Updated Protocol for Clinical Trial Evaluating (Z)-Endoxifen in Combin...
GlobeNewswire
6/21
HUTCHMED Announces European Commission Approval for FRUZAQLA® (fruquintinib) Received by Takeda
GlobeNewswire
6/19
Jasper Therapeutics Announces Appointment of Svetlana Lucas Ph.D., to its Board of Directors
GlobeNewswire
6/12
US Gastroenterologists Express Anticipation for Approval of AbbVie’s Skyrizi in Ulcerative Colitis, ...
GlobeNewswire
6/11
Global Multiple Sclerosis Drugs Market Size Projected to Reach $38 Billion By 2032 as Demand on R&D ...
GlobeNewswire
6/11
Skyhawk Therapeutics Promotes Clint Musil to Chief Executive Officer and Appoints Co-founder Bill Ha...
GlobeNewswire
6/11
Adverum Biotechnologies Announces Appointments of Dr. Rabia Gurses Ozden as Chief Medical Officer an...
GlobeNewswire
6/11
Biora Therapeutics Announces Presentation on the BioJet™ Systemic Oral Delivery Platform at the Next...
GlobeNewswire
6/10
Sermonix Pharmaceuticals Announces Breast Cancer Research Publication of Paper Examining Lasofoxifen...